Sarcopenia, defined as a decrease in muscle mass and strength, is prevalent among patients with chronic kidney disease (CKD) and is associated with adverse clinical outcomes. The ratio of creatinine- to cystatin C-based eGFR (eGFRcre/eGFRcys) and the serum creatinine-to-cystatin C ratio (sCre/sCys), which account for the influence of muscle mass, have been reported to be associated with sarcopenia. However, data concerning advanced CKD are limited, and no study has specifically examined this association in Japanese patients with CKD.
Hashimoto et al. (Wed,) studied this question.